Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
We created the first FDA-cleared device supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our four FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without requiring additional hardware.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
DAYTON, Ohio – Nov. 18, 2015–ClearRead CT by Riverain Technologies receives CE mark approval. ClearRead CT incorporates Riverain’s patent pending ClearRead CT Vessel Suppression used to improve nodule conspicuity and reduce reading time. Additionally, ClearRead CT identifies and characterizes nodules and is proven to enhance radiologists’ CT nodule detection accuracy in conjunction with decreasing reading time.
The ClearRead CT software will be introduced at the 2015 Radiological Society of North America (RSNA) annual meeting in Chicago, November 29th – December 3rd.
ClearRead CT utilizes patented image normalization technology, providing an enterprise ready solution for the entire healthcare network. The technology easily processes CT studies from a wide range of manufacturers and acquisition protocols.
ClearRead CT is available for sale in Europe and is currently being reviewed for clearance by the FDA.
For a demonstration or additional information, visit the Riverain Technologies booth at RSNA 2015 (#4108, South Building)